Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency

C. W. Taylor, T. M. Grogan, M. H A Lopez, S. P L Leong, A. Odeleye, F. J. Feo-Zuppardi, Evan M Hersh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BACKGROUND: The severe combined immune deficiency (SCID) mouse is lacking mature B and T lymphocytes and may be permissive for human tumor growth and metastasis. EXPERIMENTAL DESIGN: SCID mice received human melanoma cells of diverse origins including: 2 established cell lines, 4 early passage cell lines, and fresh or cryopreserved cells obtained directly from 9 patient biopsies. They were introduced into SCID mice via intraperitoneal, subcutaneous and intravenous injections. RESULTS: Tumor growth occurred with each of the 15 melanoma specimens for a take rate of 100% considering cell source. In addition, 60% of the 102 total mice injected displayed tumor growth in at least one site. The most consistent tumor growth (77%) occurred after intraperitoneal injection. Tumors developed in 41 and 48% of mice injected subcutaneously and intravenously, respectively. The mice developed both local tumor growth with palpable tumor nodules at injection sites and hematogenous and/or lymphatic dissemination to multiple sites in the abdominal and thoracic cavities. The number of metastases per animal averaged 16.3 and the number per organ ranged from 1 to 38. Melanotic and amelanotic tumor nodules obtained from a single patient retained their original characteristics with regard to melanin production after passage in the SCID mouse. The appearance of the human melanoma cells in SCID mouse tissues ranged from implants on the organ capsule to frank parenchymal organ involvement and vascular invasion. Some small foci of tumor were only detected using immunohistochemistry with monoclonal antibodies against the S- 100 and HMB-45 to melanoma-related antigens. CONCLUSIONS: We conclude that the SCID mouse consistently supports growth, invasion, and metastatic spread of human melanoma cells, including specimens obtained from fresh patient biopsies. The SCID mouse will serve as a relevant in vivo model for studying the biology of human malignant melanoma and screening new therapeutic agents.

Original languageEnglish (US)
Pages (from-to)130-137
Number of pages8
JournalLaboratory Investigation
Volume67
Issue number1
StatePublished - 1992

Fingerprint

Severe Combined Immunodeficiency
Melanoma
Growth
Neoplasms
Intraperitoneal Injections
Neoplasm Metastasis
Melanoma-Specific Antigens
Thoracic Cavity
Biopsy
Cell Line
Abdominal Cavity
Melanins
Subcutaneous Injections
Intravenous Injections
Capsules
Blood Vessels
B-Lymphocytes
Immunohistochemistry
Monoclonal Antibodies
T-Lymphocytes

Keywords

  • immunohistochemistry
  • Metastatic model
  • SCID mouse

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Taylor, C. W., Grogan, T. M., Lopez, M. H. A., Leong, S. P. L., Odeleye, A., Feo-Zuppardi, F. J., & Hersh, E. M. (1992). Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency. Laboratory Investigation, 67(1), 130-137.

Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency. / Taylor, C. W.; Grogan, T. M.; Lopez, M. H A; Leong, S. P L; Odeleye, A.; Feo-Zuppardi, F. J.; Hersh, Evan M.

In: Laboratory Investigation, Vol. 67, No. 1, 1992, p. 130-137.

Research output: Contribution to journalArticle

Taylor, CW, Grogan, TM, Lopez, MHA, Leong, SPL, Odeleye, A, Feo-Zuppardi, FJ & Hersh, EM 1992, 'Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency', Laboratory Investigation, vol. 67, no. 1, pp. 130-137.
Taylor CW, Grogan TM, Lopez MHA, Leong SPL, Odeleye A, Feo-Zuppardi FJ et al. Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency. Laboratory Investigation. 1992;67(1):130-137.
Taylor, C. W. ; Grogan, T. M. ; Lopez, M. H A ; Leong, S. P L ; Odeleye, A. ; Feo-Zuppardi, F. J. ; Hersh, Evan M. / Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency. In: Laboratory Investigation. 1992 ; Vol. 67, No. 1. pp. 130-137.
@article{406a00d7b4df415faad808915507c436,
title = "Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency",
abstract = "BACKGROUND: The severe combined immune deficiency (SCID) mouse is lacking mature B and T lymphocytes and may be permissive for human tumor growth and metastasis. EXPERIMENTAL DESIGN: SCID mice received human melanoma cells of diverse origins including: 2 established cell lines, 4 early passage cell lines, and fresh or cryopreserved cells obtained directly from 9 patient biopsies. They were introduced into SCID mice via intraperitoneal, subcutaneous and intravenous injections. RESULTS: Tumor growth occurred with each of the 15 melanoma specimens for a take rate of 100{\%} considering cell source. In addition, 60{\%} of the 102 total mice injected displayed tumor growth in at least one site. The most consistent tumor growth (77{\%}) occurred after intraperitoneal injection. Tumors developed in 41 and 48{\%} of mice injected subcutaneously and intravenously, respectively. The mice developed both local tumor growth with palpable tumor nodules at injection sites and hematogenous and/or lymphatic dissemination to multiple sites in the abdominal and thoracic cavities. The number of metastases per animal averaged 16.3 and the number per organ ranged from 1 to 38. Melanotic and amelanotic tumor nodules obtained from a single patient retained their original characteristics with regard to melanin production after passage in the SCID mouse. The appearance of the human melanoma cells in SCID mouse tissues ranged from implants on the organ capsule to frank parenchymal organ involvement and vascular invasion. Some small foci of tumor were only detected using immunohistochemistry with monoclonal antibodies against the S- 100 and HMB-45 to melanoma-related antigens. CONCLUSIONS: We conclude that the SCID mouse consistently supports growth, invasion, and metastatic spread of human melanoma cells, including specimens obtained from fresh patient biopsies. The SCID mouse will serve as a relevant in vivo model for studying the biology of human malignant melanoma and screening new therapeutic agents.",
keywords = "immunohistochemistry, Metastatic model, SCID mouse",
author = "Taylor, {C. W.} and Grogan, {T. M.} and Lopez, {M. H A} and Leong, {S. P L} and A. Odeleye and Feo-Zuppardi, {F. J.} and Hersh, {Evan M}",
year = "1992",
language = "English (US)",
volume = "67",
pages = "130--137",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency

AU - Taylor, C. W.

AU - Grogan, T. M.

AU - Lopez, M. H A

AU - Leong, S. P L

AU - Odeleye, A.

AU - Feo-Zuppardi, F. J.

AU - Hersh, Evan M

PY - 1992

Y1 - 1992

N2 - BACKGROUND: The severe combined immune deficiency (SCID) mouse is lacking mature B and T lymphocytes and may be permissive for human tumor growth and metastasis. EXPERIMENTAL DESIGN: SCID mice received human melanoma cells of diverse origins including: 2 established cell lines, 4 early passage cell lines, and fresh or cryopreserved cells obtained directly from 9 patient biopsies. They were introduced into SCID mice via intraperitoneal, subcutaneous and intravenous injections. RESULTS: Tumor growth occurred with each of the 15 melanoma specimens for a take rate of 100% considering cell source. In addition, 60% of the 102 total mice injected displayed tumor growth in at least one site. The most consistent tumor growth (77%) occurred after intraperitoneal injection. Tumors developed in 41 and 48% of mice injected subcutaneously and intravenously, respectively. The mice developed both local tumor growth with palpable tumor nodules at injection sites and hematogenous and/or lymphatic dissemination to multiple sites in the abdominal and thoracic cavities. The number of metastases per animal averaged 16.3 and the number per organ ranged from 1 to 38. Melanotic and amelanotic tumor nodules obtained from a single patient retained their original characteristics with regard to melanin production after passage in the SCID mouse. The appearance of the human melanoma cells in SCID mouse tissues ranged from implants on the organ capsule to frank parenchymal organ involvement and vascular invasion. Some small foci of tumor were only detected using immunohistochemistry with monoclonal antibodies against the S- 100 and HMB-45 to melanoma-related antigens. CONCLUSIONS: We conclude that the SCID mouse consistently supports growth, invasion, and metastatic spread of human melanoma cells, including specimens obtained from fresh patient biopsies. The SCID mouse will serve as a relevant in vivo model for studying the biology of human malignant melanoma and screening new therapeutic agents.

AB - BACKGROUND: The severe combined immune deficiency (SCID) mouse is lacking mature B and T lymphocytes and may be permissive for human tumor growth and metastasis. EXPERIMENTAL DESIGN: SCID mice received human melanoma cells of diverse origins including: 2 established cell lines, 4 early passage cell lines, and fresh or cryopreserved cells obtained directly from 9 patient biopsies. They were introduced into SCID mice via intraperitoneal, subcutaneous and intravenous injections. RESULTS: Tumor growth occurred with each of the 15 melanoma specimens for a take rate of 100% considering cell source. In addition, 60% of the 102 total mice injected displayed tumor growth in at least one site. The most consistent tumor growth (77%) occurred after intraperitoneal injection. Tumors developed in 41 and 48% of mice injected subcutaneously and intravenously, respectively. The mice developed both local tumor growth with palpable tumor nodules at injection sites and hematogenous and/or lymphatic dissemination to multiple sites in the abdominal and thoracic cavities. The number of metastases per animal averaged 16.3 and the number per organ ranged from 1 to 38. Melanotic and amelanotic tumor nodules obtained from a single patient retained their original characteristics with regard to melanin production after passage in the SCID mouse. The appearance of the human melanoma cells in SCID mouse tissues ranged from implants on the organ capsule to frank parenchymal organ involvement and vascular invasion. Some small foci of tumor were only detected using immunohistochemistry with monoclonal antibodies against the S- 100 and HMB-45 to melanoma-related antigens. CONCLUSIONS: We conclude that the SCID mouse consistently supports growth, invasion, and metastatic spread of human melanoma cells, including specimens obtained from fresh patient biopsies. The SCID mouse will serve as a relevant in vivo model for studying the biology of human malignant melanoma and screening new therapeutic agents.

KW - immunohistochemistry

KW - Metastatic model

KW - SCID mouse

UR - http://www.scopus.com/inward/record.url?scp=0026633056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026633056&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 130

EP - 137

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 1

ER -